 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | hydroxypropyl beta cyclodextrin (VAR 200) / ZyVersa
New P2 trial: P2a Open Label Study to Evaluate 2-HP?CD in Subjects With Diabetic Kidney Disease (clinicaltrials.gov) - Jul 4, 2024
P2, N=8, Not yet recruiting, Sponsor: ZyVersa Therapeutics, Inc.